The Food and Drug Administration this week elevated a prescription thyroid medication recall to its most serious classification because the medication is too potent.
Several weeks ago, Vitruvias Therapeutics said in a notice published by the FDA that it was voluntarily recalling one lot of thyroid tablets because the medication is “superpotent” and can “cause hyperthyroidism,” or an overactive thyroid, in some people.
The affected lot, 504950, was distributed across the United States by Alabama-based Vitruvias Therapeutics between Jan. 31, 2025. and Sept. 30, 2025. The drug’s expiration date is Sept. 30, 2026, according to the FDA notice.
In an enforcement report updated on Sept. 22, the FDA classified the thyroid tablets as a Class I recall, the most severe in its three-tiered system….